Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026
Safety Classified by Officially
Review will assess risk of low blood phosphate levels and related bone problems with injectable iron medicines
EMA’s safety committee, PRAC, has started a review of injectable iron-containing medicines following concerns about the risk of hypophosphataemia (low blood phosphate levels) and related bone problems, including osteomalacia (softening of the bones). Phosphate is important for keeping bones healthy. When phosphate levels become too low, osteomalacia can occur causing symptoms such as bone pain. In some cases, it can result in fractures.
Injectable iron-containing medicines are used to treat iron deficiency and iron deficiency anaemia (low red blood cell levels) when iron taken by mouth does not work well enough, cannot be used, or when iron levels need to be restored quickly.
Hypophosphataemia and hypophosphataemic osteomalacia (softening of the bones caused by low blood phosphate levels) are known side effects of injectable iron medicines containing the active substance ferric carboxymaltose. Hypophosphataemia is listed as a common side effect in the product information, meaning it affects up to 1 in 10 people taking the medicine. However, the frequency of hypophosphataemic osteomalacia is unknown because the available data do not allow an estimate of how often it occurs. The product information also includes measures to reduce the risk of hypophosphataemic osteomalacia including recommendations to monitor blood phosphate levels in people receiving high doses or long-term treatment and those with known risk factors.
This is an extract. The publication continues at the source.
Source: European Medicines Agency.
Read the original at the source: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-31-august-3-september-2026 This address stopped responding when last checked on November 11, 2026. The record below is what Officially captured.
Officially imported this from European Medicines Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- European Medicines Agency — imported from official source
- Official source
- https://www.ema.europa.eu/en/news.xml RSS
- Imported
- October 03, 2026 20:30
- Versions
- 1 recorded
- Identity
-
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-...